EuMederis Pharmaceuticals is a seed-phase drug discovery company based in Sugar Land, Texas. They specialize in the development of peptide pharmaceuticals with improved bioavailability and dosing schedules. Their initial focus is on creating products for pain management, controlling osteoporosis, and reversing the inflammatory component of the metabolic syndrome.

EuMederis has already conducted proof of concept studies, including compound synthesis and in vivo testing, through their network of partners in the contract research organization world. Their innovative pharmaceutical candidates use a proprietary technology called EuPort, created by their Founder, who has years of successful research experience in peptide drug candidates. EuMederis operates with a forward-thinking business plan.

They anticipate outlicensing preclinical pharmaceutical candidates and partnering with drug development companies to bring novel clinical candidates to market. They plan to leverage their proprietary technology and work with their network of contract research organization partners to carry out clinical studies efficiently. With an experienced management team, including Founder and CEO, Dr.

John J. Nestor, Jr., who has over 30 years of pharmaceutical industry experience, EuMederis is poised to become a leader in drug discovery and development